Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Current international hypertension guidelines recommend the use of combination anti-hypertensive agents for managing hypertension. The aim of this study is to determine the association between anti-hypertensive classes use in persons with hypertension with all-cause mortality and cardiovascular events.
In this study, four randomised controlled-trials – ACCORD-BP, SPRINT, TOPCAT and HDFP were included. Anti-hypertensive classes included were renin-angiotensin system inhibitors (RASi), beta-blockers (b-blocker), calcium channel blockers (CCB), loop diuretics, thiazide diuretics and mineralocorticoid receptor antagonists (MRA). The primary outcome was all-cause mortality and the secondary outcomes were cardiovascular death, hospitalisation for heart failure, myocardial infarction and stroke. The association between anti-hypertensive class use and outcomes were analysed using multivariable Cox proportional hazards regression, stratified by trial, and treated anti-hypertensive exposure as a cumulative time-dependent covariate. Mediation analyses were performed by adjusting the primary Cox model for average on-treatment systolic blood pressure. Anonymized data and materials were provided through the National Heart, Lung, and Blood Institute’s Biologic Specimen and Data Repository Information Coordinating Center.
In total, 28,181 participants with hypertension at baseline were included in this study. The pooled cohort had a mean (±SD) age of 60 (±12) years, and 12,273 (43.6%) were female. The race distribution was White; 17 680 (62.7%), Black; 6269 (22.2%) and other race; 637 (2.3%). Mean (±SD) systolic and diastolic blood pressure were 146 ± (21) and 86 (±16) mmHg respectively. During a mean (±SD) follow-up of 4.31 (±1.56) years, RASi (hazard ratio (HR) 0.92 [95% CI; 0.89-0.94], P < 0.01), CCB (HR 0.94 [95% CI; 0.90-0.98], P < 0.01), thiazide diuretic (HR 0.93 [95% CI; 0.89-0.97], P < 0.01) and MRA (HR 0.97 [95% CI; 0.94-0.99], P < 0.01) were significantly associated with reduced risk of all-cause mortality, while B-blocker (HR 1.06 [95% CI; 1.03 – 1.08], P < 0.01) and loop diuretic (HR 1.08 [95% CI; 1.05-1.11], P < 0.01) were significantly associated with increased risk per year of exposure. Mediation analyses indicated a blood-pressure independent effect of anti-hypertensive classes on all-cause mortality.
RASi use was associated with reduced risk of cardiovascular death (HR 0.92 [95% CI; 0.88-0.95], P < 0.01) while loop diuretic (HR 1.08 [95% CI; 1.05-1.12], P < 0.01) was associated with increased risk per year of exposure. RASi (HR 0.92 [95% CI; 0.88-0.96], P < 0.01) and MRA (HR 0.94 [95% CI; 0.91-0.97], P < 0.01) were associated with reduced risk of hospitalisation for heart failure. B-blocker is associated with increased risk for myocardial infarction (HR 1.06 [95%CI; 1.03-1.09], P < 0.01) and stroke (HR 1.08 [95% CI; 1.04-1.12], P <0.01) per year of exposure (Figure 1).
In patients with hypertension, RASi, CCB, thiazide diuretic and MRA use were significantly associated with lower risk of all-cause mortality, while B-blocker and loop diuretic were associated with increased risk.
